1. Home
  2. VERA vs NVCR Comparison

VERA vs NVCR Comparison

Compare VERA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$34.04

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$18.00

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERA
NVCR
Founded
2016
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
1.2B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
VERA
NVCR
Price
$34.04
$18.00
Analyst Decision
Strong Buy
Buy
Analyst Count
10
6
Target Price
$81.30
$28.08
AVG Volume (30 Days)
1.0M
1.4M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
N/A
$655,353,000.00
Revenue This Year
N/A
$7.72
Revenue Next Year
$472.48
$6.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.28
52 Week Low
$19.07
$9.82
52 Week High
$56.05
$19.25

Technical Indicators

Market Signals
Indicator
VERA
NVCR
Relative Strength Index (RSI) 44.71 60.90
Support Level $33.43 $12.66
Resistance Level $42.77 $18.80
Average True Range (ATR) 2.23 1.02
MACD -0.11 -0.28
Stochastic Oscillator 37.47 84.05

Price Performance

Historical Comparison
VERA
NVCR

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: